LDLR and hyperlipidemia: We and others have previously identified BBR as a new medicine for hyperlipidemia and type 2 diabetes because it reduces blood lipids and glucose in patients7, 8 through a multiple-target mechanism involving low-density-lipoprotein receptor (LDLR), insulin receptor (InsR), AMP-activated protein kinase (AMPK), and proprotein convertase subtilisin kexin 9 (PCSK9), among others7, 8, 9, 10, 11.